IN THE NEWS
-
FIRST-HALF 2023 SALES OF €5.6 M, DOWN 13 % ON S1 2022, AND CASH POSITION OF €4.3 M
EVRY, FRANCE, THURSDAY JULY 13, 2023, 7:30 AM - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA company specializing in cancer genomics and... Read More
-
FIRST-HALF 2023 RESULTS - SALES DOWN 13% AND RESILIENT PROFITABILITY
Evry, France, Thursday October 19, 2023, 5:45pm - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA company specializing in cancer and disease genomics, is... Read More
-
INTEGRAGEN AND BIOASTER SIGN PARTNERSHIP AGREEMENT IN GENOMICS AND TRANSCRIPTOMICS
IntegraGen and BIOASTER have been collaborating for several years on genomic and transcriptomic analyses. Driven by the desire to strengthen this relationship, the two entities have entered into a... Read More
LATEST NEWS
-
FIRST-HALF 2023 SALES OF €5.6 M, DOWN 13 % ON S1 2022, AND CASH POSITION OF €4.3 M
EVRY, FRANCE, THURSDAY JULY 13TH 2023, 7:30 AM - IntegraGen (FR0010908723 - ALINT - PEA eligible... Read More
-
FIRST-HALF 2023 RESULTS - SALES DOWN 13% AND RESILIENT PROFITABILITY
Evry, France, Thursday October 19, 2023, 5:45 pm - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), a... Read More
-
INTEGRAGEN AND BIOASTER SIGN PARTNERSHIP AGREEMENT IN GENOMICS AND TRANSCRIPTOMICS
IntegraGen and BIOASTER have been collaborating for several years on genomic and transcriptomic analyses. Driven by... Read More
-
INTEGRAGEN SUPPORTS THE ANTOINE LACASSAGNE CENTER IN NICE FOR A LARGE-SCALE RESEARCH PROJECT ON COLORECTAL CANCER PATIENTS
Founded in 1961, the Centre Antoine Lacassagne is one of 18 cancer centers... Read More
